Healthcare Industry News: Psoriatic Arthritis
News Release - June 19, 2007
HealthSonix to Launch Combination Therapy Program With a Major Pharmaceutical Company for Patients with Advanced Rheumatoid Arthritis
IRVINE, CA--(Healthcare Sales & Marketing Network)--Jun 19, 2007 -- HealthSonix, Inc. (Other OTC:HSXI.PK ) (Frankfurt:H7S.F ) announced today that it will commence joint marketing programs with its proprietary AquaSonix Therapy and a biologic therapy medication used in adults to reduce the signs and symptoms of rheumatoid arthritis, Psoriatic Arthritis, and ankylosing spondylitis."From the beginning, we have stressed that combination therapy is the future for treating the pain associated with arthritis, and we are indeed pleased that a major New York Stock Exchange listed pharmaceutical company is partnering with us in an effort to develop the 'treatment of choice' for patients suffering with rheumatoid Arthritis," said Dieter D. Doederlein, Vice President Corporate Development.
The joint marketing programs will commence in September of 2007, with immediate revenue stream to the Company. "This gives us the time to develop new promotional materials and to cross train the sales forces on the benefits of combination therapies," added Mr. Doederlein.
The biologic therapy works against the inflammatory process like other TNF blockers and has been shown to be effective in controlling symptoms of the disease. The product is indicated for reducing signs and symptoms and inhibiting the progression of structural damage in adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs.
It is widely accepted that one of the most effective treatments for the long-term management of the symptoms of immunological disorders is physical exercise. However, it has been suggested that weight-bearing exercises -- even exercise considered 'normal' -- can aggravate pain and further promote degeneration in patients with abnormal joints. This is particularly true if the joints have incongruous articular surfaces, poor alignment, ligamentous instability, or altered muscle or joint innervation, as is often the case in patients with immunological conditions.
Unfortunately this diminishes the options for the patient with joint degeneration, which often results in a discontinuation of exercise altogether. Ironically, the ensuing immobility and lack of dynamic joint loading further damage joint surfaces leading to a spiral of immobility and degeneration.
The benefits of AquaSonix Therapy for the patient with immunological disorders include provision of a reduced weight-bearing environment in which to exercise; improvement in Range Of Motion; reduction in joint and muscle stiffness; improvement in the willingness to move; improvement in functional strength and functional mobility; improvement in social and psychological factors.
"This new partnership represents a significant development in the fight against arthritis because the guidelines published by the American College of Rheumatology [ACR] for both rheumatoid and osteo arthritis stress that the combination of medications and non pharmacological therapies is the optimal way to treat the patients," said Doederlein.
HealthSonix, Inc. (Other OTC:HSXI.PK ) (Frankfurt:H7S.F ) is a publicly traded medical technology company. The Company's core products are based on proprietary, patent pending medical technologies that use sound pulses to stimulate soft tissue, muscles and sensory and mechanoreceptors in the human body to relieve pain. All pain relief treatments and products are safe, non-invasive, and have no known side effects.
More information regarding HealthSonix, Inc. and its products and services can be found on the World Wide Web at: www.HealthSonix.com or by calling the company at 1-877-622-2121.
Note: A number of statements contained in this news release are forward-looking statements, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties, including the timely development and market acceptance of products and technologies, competitive market conditions, successful integration of acquisitions, the ability to secure additional sources of financing, the ability to reduce operating expenses and other factors not set forth herein. The actual results that the Company may achieve may differ materially from any forward-looking statements due to such risks and uncertainties.
Source: HealthSonix
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.
